SHINSHIN PHARMACEUTICAL
SHINSHIN PHARMACEUTICAL, also known as Shinshin Kayaku, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in the early 20th century, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription medications and over-the-counter products. With a strong operational presence across Asia, SHINSHIN PHARMACEUTICAL is renowned for its commitment to quality and research-driven approaches. The company’s core offerings include a diverse range of pharmaceuticals that address various health conditions, setting them apart through their focus on efficacy and safety. Recognised for its contributions to the healthcare sector, SHINSHIN PHARMACEUTICAL continues to strengthen its market position, driven by a dedication to improving patient outcomes and advancing medical science.
DitchCarbon Score
How does SHINSHIN PHARMACEUTICAL's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SHINSHIN PHARMACEUTICAL's score of 14 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SHINSHIN PHARMACEUTICAL's reported carbon emissions
In 2023, SHINSHIN PHARMACEUTICAL reported significant carbon emissions totalling approximately 1,000,000,000 kg CO2e across various scopes. The breakdown of emissions is as follows: - **Scope 1 emissions**: About 2,339,310 kg CO2e - **Scope 2 emissions**: Approximately 8,219,650 kg CO2e - **Scope 3 emissions**: The most substantial contributor, with emissions from various activities including: - Business travel: 4,085,250 kg CO2e - Employee commute: 9,791,440 kg CO2e - Use of sold products: 867,672,540 kg CO2e - Downstream leased assets: 25,539,590 kg CO2e - Purchased goods and services: 4,825,029,710 kg CO2e - Waste generated in operations: 46,920 kg CO2e - Fuel and energy-related activities: 5,025,860 kg CO2e - End-of-life treatment of sold products: 17,549,590 kg CO2e - Upstream transportation and distribution: 39,393,710 kg CO2e Despite the extensive emissions data, SHINSHIN PHARMACEUTICAL has not disclosed any specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of climate pledges or commitments suggests a need for further action in addressing their environmental impact. As a pharmaceutical company, SHINSHIN PHARMACEUTICAL operates in an industry that is increasingly scrutinised for its carbon emissions, highlighting the importance of establishing clear climate commitments and reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 2,339,310 |
| Scope 2 | 8,219,650 |
| Scope 3 | 5,794,134,610 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SHINSHIN PHARMACEUTICAL is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
